MPM BioImpact’s investment team consists of professionals who have dedicated their careers to research and drug development, company creation, corporate strategy, and commercialization. This includes our Entrepreneur Partners, who provide deep domain expertise in the most innovative areas of biotechnology, capabilities across the entire drug development process, and a track record of navigating the complex regulatory landscape. We are a team of deeply experienced industry experts who help transform scientific discoveries into breakthrough medicines for the patients that need them most.
Learn about our team of expertsInvesting
in the Future
of Medicine
We invest in private and public companies across the drug development process with the goal of transforming scientific breakthroughs into life saving medicines.
We Build and Support Companies that Transform Patient Outcomes
We built Orna Therapeutics to create a new class of coding RNA medicines that outperforms mRNA.
Orna’s circular RNA technology (oRNA) and best-in-class non-viral delivery are fundamentally changing the landscape of treatment modalities,* starting with replacing cell therapies in autoimmune diseases and oncology indications.
"We are proud to have created and built Orna based on groundbreaking research that came out of MIT. Orna is combining its proprietary circular RNA platform with industry leading delivery technology to create transformative medicines using the panCAR approach.”**

Ansbert Gadicke, M.D.
Chairman
Joseph Bolen, Ph.D.
Chief Executive Officer
Frank Neumann, M.D., Ph.D.
Chief Medical Officer*Garber, K., "Orna Therapeutics: circular logic," Nature Biotechnology, 05 August 2022, https://doi.org/10.1038/d41587-022-00005-1
**Quotes are provided for the purpose of recruiting executives and academics to partner with MPM BioImpact. The quotes are provided by individuals who have a business and/or economic relationship with MPM BioImpact, and are not intended to solicit or offer investment advisory services.